Insights into the Transforming Growth Factor-β Signaling Pathway in Cutaneous Melanoma

키워드

참고문헌 (92)

1. Chin L, "Malignant melanoma: genetics and therapeutics in the genomic era", Genes Dev, 20, pp.2149~2182 (2006)
2. Jilaveanu LB, "Chemotherapy and biologic therapies for melanoma: do they work?", Clin Dermatol, 27, pp.614~625 (2009)
3. Tsao H, "Melanoma: from mutations to medicine", Genes Dev, 26, pp.1131~1155 (2012)
4. Flaherty KT, "From genes to drugs: targeted strategies for melanoma", Nat Rev Cancer, 12, pp.349~361 (2012)
5. Dutton-Regester K, "Reviewing the somatic genetics of melanoma: from current to future analytical approaches", Pigment Cell Melanoma Res, 25, pp.144~154 (2012)
6. Davies H, "Mutations of the BRAF gene in human cancer", Nature, 417, pp.949~954 (2002)
7. Meyle KD, "Genetic risk factors for melanoma", Hum Genet, 126, pp.499~510 (2009)
8. Lang JM, "A flexible multiplex bead-based assay for detecting germline CDKN2A and CDK4 variants in melanoma-prone kindreds", J Invest Dermatol, 131, pp.480~486 (2011)
9. Zuo L, "Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma", Nat Genet, 12, pp.97~99 (1996)
10. Lázár-Molnár E, "Autocrine and paracrine regulation by cytokines and growth factors in melanoma", Cytokine, 12, pp.547~554 (2000)
11. Perrot CY, "Overlapping activities of TGF-β and Hedgehog signaling in cancer: therapeutic targets for cancer treatment", Pharmacol Ther, 137, pp.183~199 (2013)
12. Javelaud D, "Transforming growth factor-beta in cutaneous melanoma", Pigment Cell Melanoma Res, 21, pp.123~132 (2008)
13. Pardali K, "Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer", Biochim Biophys Acta, 1775, pp.21~62 (2007)
14. Rodeck U, "Transforming growth factor beta production and responsiveness in normal human melanocytes and melanoma cells", Cancer Res, 54, pp.575~581 (1994)
15. Yang G, "Inhibition of PAX3 by TGF-beta modulates melanocyte viability", Mol Cell, 32, pp.554~563 (2008)
16. Kim DS, "Transforming growth factor-beta1 decreases melanin synthesis via delayed extracellular signalregulated kinase activation", Int J Biochem Cell Biol, 36, pp.1482~1491 (2004)
17. Rodeck U, "Independent regulation of growth and SMAD-mediated transcription by transforming growth factor beta in human melanoma cells", Cancer Res, 59, pp.547~550 (1999)
18. Lo RS, "Transforming growth factor-beta activation promotes genetic context-dependent invasion of immortalized melanocytes", Cancer Res, 68, pp.4248~4257 (2008)
19. Lasfar A, "Resistance to transforming growth factor β-mediated tumor suppression in melanoma: are multiple mechanisms in place?", Carcinogenesis, 31, pp.1710~1717 (2010)
20. Krasagakis K, "Elevated plasma levels of transforming growth factor (TGF)-beta1 and TGF-beta2 in patients with disseminated malignant melanoma", Br J Cancer, 77, pp.1492~1494 (1998)
21. Reed JA, "Expression of transforming growth factor-beta 2 in malignant melanoma correlates with the depth of tumor invasion. Implications for tumor progression", Am J Pathol, 145, pp.97~104 (1994)
22. Hoek KS, "Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature", Pigment Cell Res, 19, pp.290~302 (2006)
23. Javelaud D, "Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis", Cancer Res, 67, pp.2317~2324 (2007)
24. Mohammad KS, "TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases", Cancer Res, 71, pp.175~184 (2011)
25. Mnich CD, "Reduced pSmad2 immunodetection correlates with increased primary melanoma thickness", Melanoma Res, 17, pp.131~136 (2007)
26. Gaur A, "Characterization of microRNA expression levels and their biological correlates in human cancer cell lines", Cancer Res, 67, pp.2456~2468 (2007)
27. Duncan LM, "Melastatin expression and prognosis in cutaneous malignant melanoma", J Clin Oncol, 19, pp.568~576 (2001)
28. Duncan LM, "Down-regulation of the novel gene melastatin correlates with potential for melanoma metastasis", Cancer Res, 58, pp.1515~1520 (1998)
29. Levy C, "Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma", Mol Cell, 40, pp.841~849 (2010)
30. Altomonte M, "Expression and structural features of endoglin (CD105), a transforming growth factor beta1 and beta3 binding protein, in human melanoma", Br J Cancer, 74, pp.1586~1591 (1996)
31. Pardali E, "Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma", Oncogene, 30, pp.334~345 (2011)
32. Sasaki A, "Filamin associates with Smads and regulates transforming growth factor-beta signaling", J Biol Chem, 276, pp.17871~17877 (2001)
33. Yilmaz M, "Transcription factor Dlx2 protects from TGFβ-induced cell-cycle arrest and apoptosis", EMBO J, 30, pp.4489~4499 (2011)
34. Smith CC, "Restored expression of the atypical heat shock protein H11", HspB8 inhibits the growth of genetically diverse melanoma tumors through activation of novel TAK1-dependent death pathways, 2012, pp.3, e371~
35. Javelaud D, "Efficient TGF-β", SMAD signaling in human melanoma cells associated with high c-SKI, Mol Cancer, pp.2011, 10[DOI]
36. Reed JA, "Cytoplasmic localization of the oncogenic protein Ski in human cutaneous melanomas in vivo: functional implications for transforming growth factor beta signaling", Cancer Res, 61, pp.8074~8078 (2001)
37. Chen D, "SKI knockdown inhibits human melanoma tumor growth in vivo", Pigment Cell Melanoma Res, 22, pp.761~772 (2009)
38. Poser I, "Characterization of Sno expression in malignant melanoma", Int J Oncol, 26, pp.1411~1417 (2005)
39. Bosserhoff AK, "Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma", Cancer Res, 57, pp.3149~3153 (1997)
40. Rothhammer T, "Influence of melanoma inhibitory activity on transforming growth factor-beta signaling in malignant melanoma", Melanoma Res, 16, pp.309~316 (2006)
41. Javelaud D, "The TGF-β", SMAD, Cancer Res, pp.2011, 71[DOI]
42. Le Scolan E, "Transforming growth factor-beta suppresses the ability of Ski to inhibit tumor metastasis by inducing its degradation", Cancer Res, 68, pp.3277~3285 (2008)
43. Cohen-Solal KA, "Constitutive Smad linker phosphorylation in melanoma: a mechanism of resistance to transforming growth factor-β-mediated growth inhibition", Pigment Cell Melanoma Res, 24, pp.512~524 (2011)
44. Kamaraju AK, "Role of Rho", ROCK and p38 MAP kinase pathways in transforming growth factor-beta-mediated Smad-dependent growth inhibition of human breast carcinoma cells in vivo, 2005, pp.280, 1024~1036
45. Mori S, "TGF-beta and HGF transmit the signals through JNK-dependent Smad2", 3 phosphorylation at the linker regions, 2004, pp.23, 7416~7429
46. Matsuura I, "Identification and characterization of ERK MAP kinase phosphorylation sites in Smad3", Biochemistry, 44, pp.12546~12553 (2005)
47. Millet C, "A negative feedback control of transforming growth factor-beta signaling by glycogen synthase kinase 3-mediated Smad3 linker phosphorylation at Ser-204", J Biol Chem, 284, pp.19808~19816 (2009)
48. Alarcón C, "Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-beta pathways", Cell, 139, pp.757~769 (2009)
49. Matsuura I, "Cyclin-dependent kinases regulate the antiproliferative function of Smads", Nature, 430, pp.226~231 (2004)
50. Shellman YG, "Expression of activated N-ras in a primary melanoma cell line counteracts growth inhibition by transforming growth factor-beta", J Invest Dermatol, 114, pp.1200~1204 (2000)
51. Norton JD, "ID helix-loop-helix proteins in cell growth, differentiation and tumorigenesis", J Cell Sci, 113, pp.3897~3905 (2000)
52. Schlegel NC, "Id2 suppression of p15 counters TGF-beta-mediated growth inhibition of melanoma cells", Pigment Cell Melanoma Res, 22, pp.445~453 (2009)
53. Scholl FA, "PAX3 is expressed in human melanomas and contributes to tumor cell survival", Cancer Res, 61, pp.823~826 (2001)
54. Heldin CH, "Regulation of EMT by TGFβ in cancer", FEBS Lett, 586, pp.1959~1970 (2012)
55. Janji B, "Autocrine TGF-beta-regulated expression of adhesion receptors and integrin-linked kinase in HT-144 melanoma cells correlates with their metastatic phenotype", Int J Cancer, 83, pp.255~262 (1999)
56. De Craene B, "Regulatory networks defining EMT during cancer initiation and progression", Nat Rev Cancer, 13, pp.97~110 (2013)
57. Javelaud D, "Stable overexpression of Smad7 in human melanoma cells inhibits their tumorigenicity in vitro and in vivo", Oncogene, 24, pp.7624~7629 (2005)
58. DiVito KA, "Smad7 restricts melanoma invasion by restoring N-cadherin expression and establishing heterotypic cell-cell interactions in vivo", Pigment Cell Melanoma Res, 23, pp.795~808 (2010)
59. Xavier S, "Amelioration of radiation-induced fibrosis: inhibition of transforming growth factor-beta signaling by halofuginone", J Biol Chem, 279, pp.15167~15176 (2004)
60. Juárez P, "Halofuginone inhibits the establishment and progression of melanoma bone metastases", Cancer Res, 72, pp.6247~6256 (2012)
61. Dennler S, "Induction of sonic hedgehog mediators by transforming growth factor-beta: Smad3-dependent activation of Gli2 and Gli1 expression in vitro and in vivo", Cancer Res, 67, pp.6981~6986 (2007)
62. Dennler S, "Cloning of the human GLI2 Promoter: transcriptional activation by transforming growth factor-beta via SMAD3", beta-catenin cooperation, 2009, pp.284, 31523~31531
63. Alexaki VI, "GLI2-mediated melanoma invasion and metastasis", J Natl Cancer Inst, 102, pp.1148~1159 (2010)
64. Dissanayake SK, "Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation", Cancer Res, 68, pp.10205~10214 (2008)
65. Reddy S, "Characterization of Wnt gene expression in developing and postnatal hair follicles and identification of Wnt5a as a target of Sonic hedgehog in hair follicle morphogenesis", Mech Dev, 107, pp.69~82 (2001)
66. Sterling JA, "The hedgehog signaling molecule Gli2 induces parathyroid hormone-related peptide expression and osteolysis in metastatic human breast cancer cells", Cancer Res, 66, pp.7548~7553 (2006)
67. Girotti MR, "SPARC promotes cathepsin B-mediated melanoma invasiveness through a collagen I", α2β1 integrin axis, 2011, pp.131, 2438~2447
68. Ungerer C, "ADAM15 expression is downregulated in melanoma metastasis compared to primary melanoma", Biochem Biophys Res Commun, 401, pp.363~369 (2010)
69. Trochon-Joseph V, "Evidence of antiangiogenic and antimetastatic activities of the recombinant disintegrin domain of metargidin", Cancer Res, 64, pp.2062~2069 (2004)
70. Yin M, "TGF-β signaling, activated stromal fibroblasts, and cysteine cathepsins B and L drive the invasive growth of human melanoma cells", Am J Pathol, 181, pp.2202~2216 (2012)
71. Sun J, "Fascin protein is critical for transforming growth factor β proteininduced invasion and filopodia formation in spindle-shaped tumor cells", J Biol Chem, 286, pp.38865~38875 (2011)
72. Nummela P, "Transforming growth factor beta-induced (TGFBI) is an anti-adhesive protein regulating the invasive growth of melanoma cells", Am J Pathol, 180, pp.1663~1674 (2012)
73. Onichtchouk D, "Silencing of TGF-beta signalling by the pseudoreceptor BAMBI", Nature, 401, pp.480~485 (1999)
74. Degen WG, "Expression of nma, a novel gene, inversely correlates with the metastatic potential of human melanoma cell lines and xenografts", Int J Cancer, 65, pp.460~465 (1996)
75. Berking C, "Transforming growth factor-beta1 increases survival of human melanoma through stroma remodeling", Cancer Res, 61, pp.8306~8316 (2001)
76. Zeisberg EM, "Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts", Cancer Res, 67, pp.10123~10128 (2007)
77. Liu G, "Selective induction of interleukin-8 expression in metastatic melanoma cells by transforming growth factor-beta 1", Cytokine, 31, pp.241~249 (2005)
78. Orecchia P, "Identification of a novel cell binding site of periostin involved in tumour growth", Eur J Cancer, 47, pp.2221~2229 (2011)
79. Penafuerte C, "Novel TGF-beta antagonist inhibits tumor growth and angiogenesis by inducing IL-2 receptordriven STAT1 activation", J Immunol, 186, pp.6933~6944 (2011)
80. Nesbit M, "Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells", J Immunol, 166, pp.6483~6490 (2001)
81. Dirkx AE, "Monocyte", macrophage infiltration in tumors: modulators of angiogenesis, 2006, pp.80, 1183~1196
82. Chen Q, "Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma", Int J Cancer, 56, pp.755~760 (1994)
83. Moretti S, "Serum imbalance of cytokines in melanoma patients", Melanoma Res, 11, pp.395~399 (2001)
84. Nemunaitis J, "Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma", Cancer Invest, 19, pp.239~247 (2001)
85. Díaz-Valdés N, "Induction of monocyte chemoattractant protein-1 and interleukin-10 by TGFbeta1 in melanoma enhances tumor infiltration and immunosuppression", Cancer Res, 71, pp.812~821 (2011)
86. Oettle H, "Final results of a phase I", II study in patients with pancreatic cancer, malignant melanoma, and colorectal carcinoma with trabedersen, 2012, pp.30(Suppl), ~
87. Connolly EC, "Complexities of TGF-β targeted cancer therapy", Int J Biol Sci, 8, pp.964~978 (2012)
88. Morris JC, "Phase I", II study of GC1008: A human anti-transforming growth factor-beta (TGFβ) monoclonal antibody (MAb) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC), 2008, pp.26(20 Suppl), ~
89. Orphanos GS, "Cardiotoxicity induced by tyrosine kinase inhibitors", Acta Oncol, 48, pp.964~970 (2009)
90. Olivares J, "Phase I trial of TGF-beta 2 antisense GM-CSF genemodified autologous tumor cell (TAG) vaccine", Clin Cancer Res, 17, pp.183~192 (2011)
91. Senzer N, "Phase I trial of "bi-shRNAi(furin)", GMCSF DNA, Mol Ther, pp.2012, 20[DOI]
92. Park J, "Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy", Nat Mater, 11, pp.895~905 (2012)

관련 논문AI추천